viewCello Health PLC

Cello Group chief: US growth down to added capabilities and skills

The chief executive of healthcare marketing specialist Cello Group (LON:CLL), Mark Scott, explains how the business is expanding in the US with its two divisions - Health and Signal .

Cello Health provides science-led market intelligence and advice for the pharmaceuticals and biotechnology industries, enjoyed strong headline revenue growth.

Earlier this year the company opened an office in Boston, targeting the growing pharmaceutical community in the area.

On the West Coast, the company is beefing up its presence in San Francisco to capitalise on the growing number of biotech companies operating in California.

Quick facts: Cello Health PLC

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...


Cello Group hails the impact of a “vibrant” US on the company’s performance

Chief executive of Cello Group (LON:CLL) Mark Scott spoke to Proactive’s Charlotte Kan in the wake of an upbeat trading update from healthcare and strategic consumer marketing specialist. The research and communications operations both performed well, but there was a common theme to update...

on 05/11/2016

2 min read